InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure

Animal model for the study of Chronic Myocardial Infarction indicates, for the first time, regenerative potential in a pig’s heart using uncultured autologous adipose-derived regenerative cells prepared at point of care. Houston, TX, USA, October 31, 2019 – InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform. A newly-released research paper published in the World Journal of Stem Cells provides missing pieces of evidence for a fundamental change in the treatment of chronic ischemic heart failure, showing efficacy and safety of a novel stem cell treatment in cardiology. Patients with heart failure as a consequence of previous myocardial infarction are a large and currently underserved patient population, due to the lack of regenerative treatment options. The publication, performed in a pig model for the study of chronic myocardial infarction, evidence for the first time that regeneration of the damaged tissue in the heart – responsible for chronic ischemic heart failure – is possible. Specifically, the study demonstrates that InGeneron’s fresh, uncultured, autologous adipose-derived regenerative cells (UA-ADRCs) – isolated and administered at the point of care – provide a significant improvement of cardiac circulatory parameters in chronic ischemic heart failure. The results show that the mean cardiac output increased by 37%, the mean left ventricular mass increased by 29% and the mean relative amount of scar volume of the left ventricular wall decreased by 21% six weeks after treatment with the cells. All results were statistically significant compared to the control group. Notably, on average only 18 gram of adipose tissue were required to recover the averaged 18 million cells injected to achieve the reported effects. The findings represent an important step in research, laying the foundation for new frontiers on cardiac regeneration of chronic ischemic heart failure in human patients. While previous studies indicated that stem cells (including UA-ADRCs) might be of benefit in acute myocardial infarction, this benchmark had previously not been achieved by studies of autologous stem cells for chronic heart failure following myocardial infarction. Haenel et al., the authors of the publication, attribute the success of the study to two important improvements over previous attempts. The primary success factor was the use of InGeneron’s technology for isolating the stem cells at the point of care. In this regard, a recent publication by Winnier et al. ( PLoS One 2019;14:e0221457 ) demonstrated that the technology used (Transpose®RT / Matrase™; InGeneron, Inc., Houston, TX, USA), provides the highest published number of living, uncultured, autologous, adult pluripotent stem cells recovered per gram of adipose tissue. The second differentiator to all previously published results for myocardial regeneration is the application method to the damaged heart. Haenel et al. administered the stem cells retrograde through the heart’s venous system, precisely to the area in need of regeneration. This retrograde injection technique, combined with a temporary blockage of the coronary vein at the level of a previous arterial occlusion, allowed the stem cells to overcome the endothelial barrier and thereby created a homogenous distribution of injected cells throughout the damaged myocardial tissue. Dr. Eckhard Alt, Executive Chair of InGeneron, Inc. and senior author of the study, commented “this therapy, which may be performed in an ambulatory setting without the known risks associated with major anticoagulation, delivers the stem cells in about 15 minutes and involves a total treatment time of approximately 3 hours. This gives hope that millions of patients suffering from chronic ischemic heart failure might benefit from rebuilding the heart with their own stem cells”. The study, entitled “ Unmodified autologous stem cells at the point of care for chronic myocardial infarction “, by Haenel et al. was published in the World Journal of Stem Cells on October 26, 2019. While the company is advancing its ongoing clinical programs for key orthopaedic conditions, additional studies are designed to validate the clinical potential of stem cells in patients with coronary artery disease and chronic heart failure. About the Transpose ® RT System and FDA approved clinical trials InGeneron’s Transpose ® RT cell therapy platform consists of a processing unit, a set of disposables and Matrase ® , a proprietary enzyme mixture. The platform allows the isolation of regenerative cells from the patients’ own adipose tissue at point-of-care in less than 90 minutes for same-day treatment. The cells are re-administered into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance. The Transpose® RT System is being investigated in several FDA-approved clinical trials and is currently available in the U.S. for research use only. More information on InGeneron’s actively enrolling clinical trials can be found at www.clinicaltrials.gov under the identifiers NCT03752827 , NCT03513731 , and NCT03503305 . About InGeneron InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Based on more than 20 years of research, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA. www.ingeneron.com Contacts: InGeneron, Inc. Eckhard Alt, MD, PhD Executive Chairman of InGeneron +1 (713) 440 9900 [email protected] Media Inquiries Jon Stone Stone Communications Consulting +1 (612) 475 5955 [email protected] Recent Posts Press Releases Feb 4, 2026 InGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical Devices Press Releases Jul 23, 2025 InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System Press Releases Nov 13, 2023 InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears Press Releases Nov 3, 2023 InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial Press Releases Jan 6, 2023 New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups Press Releases Jan 24, 2022 InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics Press Releases Jan 6, 2022 American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears News Nov 23, 2021 InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body Press Releases Jul 23, 2021 InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment Press Releases Apr 7, 2020 InGeneron Announces Publication of Rotator Cuff Feasibility Study Press Releases Oct 31, 2019 InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure News Jun 11, 2019 InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic Press Releases May 15, 2019 InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy Press Releases Mar 21, 2019 InGeneron Announces Publication of Results from First-in-Human Case Report of its Cell Therapy in Bone Regeneration News Jan 23, 2019 InGeneron Expands Development Pipeline with Two Osteoarthritis Programs News Dec 12, 2018 InGeneron Reports Positive Top-Line Data From its Clinical Lead Program in Rotator Cuff Tendinopathy News Sep 18, 2017 InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology News Mar 6, 2017 InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies News Dec 5, 2016 InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences News Nov 21, 2016 InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS Have any Questions ? Important In the US InGeneron’s Transpose ® RT cell therapy platform is for investigational use only. By Clicking ‘Continue’ I confirm acknowledgment Continue Our mission is to enable novel, safe, and evidence-based therapies by unlocking the healing potential of each patient’s own regenerative cells. Twitter Linkedin Facebook 2 Youtube InGeneron, Inc. 8205 El Rio St Houston, TX 77054 USA +1 (713) 440 9900 [email protected] Subscribe to our Newsletter © 2026 by InGeneron, Inc. Site info . All rights reserved. Web Design & Development by BelugaLab Privacy Policy

The release as fetched from its publisher. ingeneron.com ↗